UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of
Report (Date of Earliest Event Reported): October 4,
2010
PDL
BioPharma, Inc.
(Exact
name of Company as specified in its charter)
000-19756
(Commission
File Number)
|
Delaware
|
94-3023969
|
|
|
(State
or Other Jurisdiction of
|
(I.R.S.
Employer Identification No.)
|
|
|
Incorporation)
|
932
Southwood Boulevard
Incline
Village, Nevada 89451
(Address
of principal executive offices, with zip code)
(775)
832-8500
(Company’s
telephone number, including area code)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the Company under any of the following
provisions:
|
¨
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
|
¨
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
¨
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
|
¨
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
Item
5.02 Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain
Officers.
On
October 4, 2010, Karen Wilson, our Vice President of Finance and Principal
Accounting Officer, announced that she will be leaving PDL BioPharma, Inc. (the
“Company”) in January 2011 to return to California. Ms. Wilson, who
joined the Company in April 2009, was instrumental in helping the Company
accomplish many transition-related goals relating to both the spin-off of Facet
Biotech Corporation and the Company’s relocation to Nevada. Ms.
Wilson has made a number of significant contributions to the Company, including
the winding-up of certain pre-2009 activities and helping establish the
infrastructure necessary to facilitate the Company’s accounting and financial
reporting going forward. The Company thanks Karen for her numerous
contributions and wishes her continued success in her future
ventures.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Company has duly
caused this report to be signed on its behalf by the undersigned hereunto duly
authorized.
| PDL BIOPHARMA, INC. | |||
| (Company) | |||
|
|
By:
|
/s/ Christopher Stone | |
| Christopher Stone | |||
| Vice President, General Counsel and Secretary | |||
Dated: October
7, 2010